WINNIPEG, MB, Nov. 22, 2021 /CNW/ - Medicure Inc. ("Medicure"
or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on
the development and commercialization of pharmaceuticals and
healthcare products for patients and prescribers in the United States market, is pleased to
announce that it is planning to launch a national
direct-to-consumer E-Commerce pharmacy platform through its
subsidiary, Marley Drug™ pharmacy, before the end of 2021.
Marley Drug's new E-Commerce website will be a platform where
FDA approved medications can be purchased at discount prices by
Americans for home delivery in all 50 States, including
ZYPITAMAG® (pitavastatin) tablets.
A primary goal of the platform is to bypass the traditional
framework run by health insurers and pharmacy benefit managers that
have made access to affordable medications challenging for many
Americans, including both generic and branded products such as
ZYPITAMAG. More than 120 million uninsured and underinsured
Americans struggle to access affordable medications and are looking
for a trusted and convenient source to fill their prescriptions.
Marley Drug will offer industry leading pricing on more than 100 of
the most commonly prescribed generic medications with free
nationwide delivery. The platform will focus on ease-of-use and
customer service, and is differentiated by being able to ship to
every US state.
Notably, the pharmacy platform addresses 'pharmacy deserts' that
exist across the country. A 'pharmacy desert' is defined as a
geographic area where Americans can't fill a prescription within a
half-a-mile of their homes (for low-income people without cars),
and a mile for others. This lack of quick access to a pharmacy
affects many Americans.
"This marks a natural progression for Medicure's Marley Drug
online pharmacy, which originated as a brick-and-mortar operation
more than 17 years ago and is being developed into a national
direct-to-consumer E-Commerce platform. This evolution will mark
the start of an exciting new chapter for our company," said
Albert D. Friesen, PhD, Chief
Executive Officer of Medicure and Chair of its Board of Directors.
"We look forward to growing and developing this E-Commerce platform
over the next few months in innovative ways to bring affordable
medication to all Americans. The combined business will be well
positioned to strengthen our existing lines of business which
include Medicure's primary care drug, ZYPITAMAG and future branded
products, and ultimately to generate substantial shareholder
value."
About Medicure Inc.
Medicure is a pharmaceutical company focused on the development
and commercialization of pharmaceuticals and healthcare products
for patients and prescribers in the
United States market. The present focus of the Company is
the marketing and distribution of AGGRASTAT® (tirofiban
hydrochloride) injection and ZYPITAMAG® (pitavastatin)
tablets in the United States,
where they are sold through the Company's U.S. subsidiary, Medicure
Pharma Inc. Medicure also operates Marley Drug™, Inc. ("Marley
Drug"), a pharmacy located in North
Carolina that offers an Extended Supply drug program serving
all 50 states, Washington D.C. and
most territories, including Puerto
Rico. Marley Drug is committed to improving the health
status of its patients and the communities they serve while
reducing overall health care costs for employers and other health
care consumers. For more information visit www.marleydrug.com. To
learn more about The Extended Supply Generic Drug Program call
800.286.6781 or e-mail info@marleydrug.com . For more information
on Medicure please visit https://www.medicure.com/. For additional
information about AGGRASTAT®, refer to the full
Prescribing Information. For additional information about
ZYPITAMAG®, refer to the full Prescribing
Information.
To be added to Medicure's e-mail list, please
visit:
https://medicure.mediaroom.com/alerts
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in policies of the TSX Venture
Exchange) accepts responsibility for the adequacy or accuracy of
this release.
Forward Looking Information: Statements contained in this press
release that are not statements of historical fact, including,
without limitation, statements containing the words "believes",
"may", "plans", "will", "estimates", "continues", "anticipates",
"intends", "expects" and similar expressions, may constitute
"forward-looking information" within the meaning of applicable
Canadian and U.S. federal securities laws (such forward-looking
information and forward-looking statements are hereinafter
collectively referred to as "forward-looking statements").
Forward-looking statements, include estimates, analysis and
opinions of management of the Company made in light of its
experience and its perception of trends, current conditions and
expected developments, as well as other factors which the Company
believes to be relevant and reasonable in the circumstances.
Inherent in forward-looking statements are known and unknown risks,
uncertainties and other factors beyond the Company's ability to
predict or control that may cause the actual results, events or
developments to be materially different from any future results,
events or developments expressed or implied by such forward-looking
statements, and as such, readers are cautioned not to place undue
reliance on forward-looking statements. Such risk factors include,
among others, the Company's future product revenues, expected
results, including future revenue from P5P, the likelihood of
receiving a PRV, expected future growth in revenues, stage of
development, additional capital requirements, risks associated with
the completion and timing of clinical trials and obtaining
regulatory approval to market the Company's products, the ability
to protect its intellectual property, dependence upon collaborative
partners, changes in government regulation or regulatory approval
processes, and rapid technological change in the industry. Such
statements are based on a number of assumptions which may prove to
be incorrect, including, but not limited to, assumptions about:
general business and economic conditions; the impact of changes in
Canadian-US dollar and other foreign exchange rates on the
Company's revenues, costs and results; the timing of the receipt of
regulatory and governmental approvals for the Company's research
and development projects; the availability of financing for the
Company's commercial operations and/or research and development
projects, or the availability of financing on reasonable terms;
results of current and future clinical trials; the uncertainties
associated with the acceptance and demand for new products and
market competition. The foregoing list of important factors and
assumptions is not exhaustive. The Company undertakes no obligation
to update publicly or otherwise revise any forward-looking
statements or the foregoing list of factors, other than as may be
required by applicable legislation. Additional discussion regarding
the risks and uncertainties relating to the Company and its
business can be found in the Company's other filings with the
applicable Canadian securities regulatory authorities or the US
Securities and Exchange Commission, and in the "Risk Factors"
section of its Form 20F for the year ended December 31, 2020.
View original
content:https://www.prnewswire.com/news-releases/medicure-plans-to-launch-innovative-e-commerce-pharmacy-platform-offering-hundreds-of-medications-directly-to-millions-of-americans-301429864.html
SOURCE Medicure Inc.